ingredients in glp 1 injections Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy Nutritional priorities to support GLP-1

In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity

Lancet 2021;398:14355.ArticlePubMed 32

Over 16 weeks, the median body weight dropped from 223 lbs (101 kg) to 203 lbs (92 kg)

If the results of conservative management are limited, surgery is a worthwhile consideration in the appropriate patient with reported efficacy in the literature (48)

GLP-1s Associated with Reduced Asthma Exacerbation in Patients Without Diabetes

Context: The expiry of semaglutide patents in India has enabled the entry of cheaper generic versions of GLP-1 receptor agonists, widely used for Type-2 diabetes and obesity management